Biodegradation of solid lipid nanoparticles as a function of lipase incubation time
Biodegradation of solid lipid nanoparticles as a function of lipase incubation time
复制标题
DOI：
10.1016/s0378-5173(96)04731-x
复制
发表时间：
1996-11-22
影响因子：
5.8
通讯作者：
Runge, SA
中科院分区：
文献类型：
--
作者：
Muller, RH;Ruhl, D;Runge, SA
研究了固体脂质纳米粒（SLN）在胰脂肪酶/辅脂肪酶溶液中的体外降解。降解后，SLN悬浮液的浊度测量和形成的游离脂肪酸（FFA）的测定。发现降解速度取决于脂质基质的性质，Dynasan 114的降解速度最高，十六烷基棕榈酸酯的降解速度中等，脂肪酸链较长的脂质（Compritol ATO 888）的降解速度相对较慢。用于SLN稳定化的表面活性剂对降解速率有主导作用。使用空间稳定的泊洛沙姆188可以防止可良好降解的Dynasan 114颗粒的体外降解。这是由于缺乏锚定的脂肪酶的颗粒表面的酶降解的先决条件。利用表面活性剂的主要作用，设计具有最佳降解速度和基质控制药物释放的SLN-不依赖于脂质基质的性质。
The in vitro degradation of solid lipid nanoparticles (SLN) was studied in solutions of pancreatic lipase/colipase. Degradation was followed by turbidity measurements of SLN suspensions and by the determination of the formed free fatty acids (FFA). The degradation velocity was found to depend on the nature of the lipid matrix, being highest for Dynasan 114, medium for cetylpalmitate and relatively slow for lipids with longer fatty acid chains (Compritol ATO 888). The surfactant used for SLN stabilization had a dominating effect on degradation velocity. Use of the sterically stabilizing poloxamer 188 could prevent the in vitro degradation of well-degradable Dynasan 114 particles. This was attributed to the lack of anchoring of the lipase to the particle surface-prerequisite for enzymatic degradation. The dominating effect of the surfactant be exploited to design SLN with optimum degradation velocity and matrix-controlled drug release-independent on the nature of the lipid matrix.